- Lilly to invest extra $4.5B across Indiana manufacturingThe Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss drugs.BioPharma Dive · 2mo ago↗ source
- FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extendedPierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere, Argenx swapped CEOs and Blackstone made a $250 million biotech investment.BioPharma Dive · 2mo ago↗ source
- Lilly, Gilead lead pharma’s M&A boomDeal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune disease drugs.BioPharma Dive · 2mo ago